No abstract

Objetive: discuss the importance of multidisciplinary care for patients undergoing Hematopoietic Stem Cell Transplantation (HSCT) based on the transdisciplinary care. Method: This is a theoretical essay discussing. Results: Each year, about 50 million people are undergoing HSCT worldwide. This therapeutic strategy is used for some oncological, hematological or immunological, malignant and non-malignant inherited or acquired diseases. during the steps after HSCT, patients, and their families experience moments of anxiety, anguish and uncertainty that cause stress and interfere with their daily lives. The multidisciplinary team working in HSCT service provide complex and specialized care since this scenario requires specific knowledge of the area. However, they do not relieve the interweaving of new knowledge for an interdisciplinary practice that meets the patient´s health needs in this delicate moment of his life. From this perspective, health professionals of HSCT service should excel by constantly learning and dynamic interventions and sharing of knowledge in the multidisciplinary team that includes a complex and transdisciplinary care. Conclusion: This essay causes the discussion about care in HSCT based on transdisciplinary care. It should be emphasized the responsibility of each member of the multidisciplinary team for the contribution and strengthening of the patient´s quality of life. In a way, the interdisciplinary care permeates the complexity in an open perspective of approximation of the various areas of knowledge.

Introduction: Hematopoietic Stem Cell Transplantation (HSCT) is a treatment modality for oncology and hematological diseases genetically inherited or acquired. The morbidities and mortalities related to HSCT are evident in its different phases, such as the Graft Versus Host Disease especially on dry eye syndrome, one of the most complication of chronic phase, characterized as a multifactorial disease of the ocular surface. Several treatments may be directed to the dry eye and the consequences caused by it during the HSCT post-period.Objective: To reveal the treatments for dry eye in patients after HSCT period.Method: This is a literature integrative review performed by the SCOPUS databases, National Library of Medicine (PubMed); Web of Science and Cumulative Index to Nursing and Allied Heath Literature (CINAHL). Results:Of the 1,551 articles identified, there were 21 in the final sample. Regarding the treatments addressed, the most often used was found the cyclosporine 0.05%, followed by allogeneic and autologous drops. Conclusion:There was no consensus identified as the best type of treatment for these patients. However, it is known that depend mainly on clinical features of chronic graft-versus-host eye on the post-transplantation situation.

Fibrinolytic Therapy (FT) is an important form of treatment for cases of Acute Myocardial Infarction (AMI), especially in those places where Primary Percutaneous Coronary Intervention (PPCI) is not available, which is the main form of treatment and can be used even in the prehospital care. Aimed to describe the clinical outcomes of the use of FT in prehospital care for treating patients with AMI. This research covered a total of 53 patients and was carried out from march to october 2017, referring to the care provided from january 2015 to december 2016 in two stages, in which the first occurred with the Mobile Emergency Service (SAMU) and Walk-in Emergency Care Units (UPA), and the second in the referenced hospital services as gateways to those units. Data were collected from secondary sources. The clinical outcomes of FT considered in the form of absolute and relative frequencies and measures of central tendency were considered. The main signs and symptoms at admission were chest pain (84.62%), sweating (36.54%), dyspnea (26.92%), hypertension (19.23%), nausea (17.31%), malaise (17.31%) and emesis (13.46%). The main characteristic of chest discomfort was chest pain (70.45%). The FT drug administered in all patients was tenecteplase. The median time from symptom-to-door was 180 minutes, while symptom-reperfusion was 300 minutes and door-to-needle 160 minutes. Regarding the outcome, 74.47% had clinical improvement, 19.15% died, 4.25% had refractory AMI and 2.13% had reinfarction. The main characteristic of clinical improvement was the reversal of chest pain (68.57%), characterized as myocardial reperfusion criteria. The present study presented the main outcomes of FT use with improvement of those patients who were treated with it, and shorter times related to chest discomfort and the administration of FT were responsible for increasing the outcomes of clinical improvement and decreasing the outcome of death.